Dr. Lili Mao 毛丽丽
Chief Physician
Medical Oncology, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Melanoma, soft tissue sarcoma, renal cancer, urothelial cancer, and squamous cell carcinoma. Focuses on immunotherapy, targeted therapy (including BRAF mutations), and chemotherapy.
Dr. Mao is a Chief Physician with an MD. In 2012, Dr. Mao completed visiting studies at the Cancer Centre of Westmead Hospital and the Melanoma Institute Australia (MIA) in Sydney. Clinical practice includes targeted therapy, immunotherapy, and chemotherapy for melanoma, renal cancer, and urothelial cancer.
Name order: in Chinese the family name comes first (Mao Lili). Papers usually list the name as Lili Mao or Mao L.
Selected publications
99 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Nat Commun, 2026 (first author): A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma. PubMed 42140948
- Ther Adv Med Oncol, 2026 (senior author): Anti-PD-1 matches interferon as adjuvant therapy for acral melanoma: a retrospective study. PubMed 42052130
- JAMA Oncol, 2023 (first author): Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial. PubMed 37261804
- Eur J Cancer, 2022 (first author): A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma. PubMed 36113242
- Clin Cancer Res, 2022 (first author): Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study. PubMed 36044526
- Front Oncol, 2021 (first author): Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial. PubMed 34504796
- Front Immunol, 2021 (first author): Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions. PubMed 34149718
- Eur J Cancer, 2021 (first author): Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway. PubMed 33770575
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion